Dataset Information

Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.

ABSTRACT:

Background

A few studies in the last several years have shown that metabolomics, the study of metabolites and small intermediate molecules, may help better understand the breast carcinogenesis. However, breast cancer is a heterogeneous disease with different subtypes. Additionally, there is a significant racial difference in terms of breast cancer incidence and mortality. Few, if any, metabolomics studies in breast cancer have considered race and tumor subtypes in the study design.

Methods

We performed a global metabolomic profiling using mass spectrometry and samples from 60 breast cancer cases and 60 matched controls.

Results

A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10). Most of those differentiated metabolites belong to amino acids, fatty acids, and lysolipids. In the pathway-based analysis, we found that plasma levels of many amino acids were statistically significantly lower in patients with breast cancer, especially those with triple-negative breast cancer, than healthy controls. However, plasma levels of many FAs related to ?-oxidation were statistically significantly higher in patients with breast cancer than healthy controls, suggesting the possibility of altered FA ?-oxidation in patients with breast cancer.

Conclusions

Because of small sample size, the clinical usage of the metabolites from this study is unclear. Further validation of those significant metabolites is warranted, especially with the consideration of racial difference.

SUBMITTER: Shen J

PROVIDER: S-EPMC3890711 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.

Shen Jie J Yan Li L Liu Song S Ambrosone Christine B CB Zhao Hua H

Translational oncology 20131201 6

<h4>Background</h4>A few studies in the last several years have shown that metabolomics, the study of metabolites and small intermediate molecules, may help better understand the breast carcinogenesis. However, breast cancer is a heterogeneous disease with different subtypes. Additionally, there is a significant racial difference in terms of breast cancer incidence and mortality. Few, if any, metabolomics studies in breast cancer have considered race and tumor subtypes in the study design.<h4>Me ...[more]

PMID: 24466379

Similar Datasets

Project description:BackgroundSocioeconomic and health care utilization factors are major drivers of prostate cancer (PC) mortality disparities in the USA; however, tumor molecular heterogeneity may also contribute to the higher mortality among Black men.ObjectiveTo compare differences in PC subtype frequency and genomic aggressiveness by self-identified race.Design setting and participantsFive molecular subtype classifiers were applied for 426 Black and 762 White PC patients in the Decipher Genomics Resource Information Database (GRID).Outcome measurements and statistical analysisDifferences in subtype frequency and tumor genomic risk (Decipher score >0.6) by race were evaluated using χ2 tests and multivariable-adjusted logistic regression models.Results and limitationsSubtype frequencies differed by race for four classifiers. Subtypes characterized by the presence of SPOP mutations, SPINK1 overexpression, and neuroendocrine differentiation were more common among Black men. ERG and ETS fusion-positive subtypes were more frequent among White men, with no clear differences for subtypes reflecting luminal versus basal lineage. The hypothesized low-risk Kamoun S2 subtype was associated with a lower Decipher score among White men only (p = 0.01 for heterogeneity), while the aggressive You PCS1 subtype was associated with a higher Decipher score among White men only (p = 0.001 for heterogeneity). The Tomlins ERG+ subtype was associated with a higher Decipher score relative to all other subtypes among Black men, with no association among White men (p = 0.007 for heterogeneity).ConclusionsThe frequency of PC molecular subtypes differed by self-identified race. Additional studies are required to evaluate whether our observations suggest differences in the tumor genomic risk of progression by self-identified race.Patient summaryWe studied five classifiers that identify subtypes of prostate tumors and found that subtypes differed in frequency between Black and White patients. Further research is warranted to evaluate how differences in tumor subtypes may contribute to disparities in prostate cancer mortality.

Dataset Information

Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.

Background

Methods

Results

Conclusions

Publications

Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets